Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Multimedia Available: Charles River Laboratories Launches Endosafe-PTS

--(BUSINESS WIRE)--

Charles River Laboratories International Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies, launched the Endosafe(R)-PTS today. The PTS is a portable test system based on the Limulus Amebocyte Lysate (LAL) assay. The LAL test is used to detect microbial contaminants in injectable drugs and medical devices.

    You can reach the story directly by going to
http://www.newstream.com/cgi-bin/display_story.cgi?10305 

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.


    CONTACT: Newstream.com, New York
             info@newstream.com

    SOURCE: Newstream and Charles River Laboratories International
Inc. 

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)